A new technology that enables a diagnosis of cardiovascular diseases only through eye images was first opened. The vessels in eyes which reflect the overall body condition enables to expect risks of a range of diseases. Early this year, Verily have suggested a possibility of expecting basic biomarkers including age, blood pressure, and smoking preference only using fundus photographs. This technology, however, has suggested a much stronger cardiovascular biomarker.
Medi Whale Inc. said, on last 2nd, December, that they have developed a system that enables to predict a coronary artery calcium score(CACS) only using the basic patient information and fundus photographs. This startup is developing a diagnosis system based on fundus photography. They said that this result is from the medical data collected from about 50,000 eye images scanned from last April to October, which was analyzed by machine learning. When predicting the coronary artery calcium score(CACS) became possible using the artificial intelligence(AI), such technology is expected to be applied for a convenient health diagnosis system.
Until now, the coronary artery calcium score(CACS) was checked through a heart CT, which has some side effects that it gives radiation exposure and possibly cause an allergic reaction for contrast medium or toxic nephrosis. “Artificial intelligence(AI) in medical field can perform as a specialized doctor when medical infrastructure is not qualified enough, support doctors to find out lesions that are easily missed, or even suggest innovative diagnosis biomarkers beyond preexisting diagnostic tools,” said Kevin Choi, CEO of Medi Whale, “the technology we suggested is sharing the idea of Verily but have achieved a stronger prediction model.” He also said that “Medi Whale Inc. is aiming to suggest the fastest way to find diseases by observing the human eyes with the artificial intelligence,” and that they are expecting to “expand the range of such detective diseases to the overall human body, starting with the artificial intelligence diagnostic device for eye diseases.”
The technology was recently opened to the public at Radiological Society of North America(RSNA) 2018, which took place in Chicago, U.S.. Medi Whale Inc. said that they are going through additional data collection and verification in order to sustain a high diagnostic ability of the model in clinical trials. The eye disease diagnostic device using artificial intelligence, which was announced by Medi Whale Inc. early this year, is on a to achieve approval of Korean Food and Drug Administration.
More information at : http://www.viva100.com/main/view.php?key=20181202010000164